3 min read
Scientific understanding does not stand still. But what happens if the understanding of bacterial species changes after the patent was filed so that an exemplified microorganism no longer belongs to the species recited in the claim?
That was one of the more newsworthy questions considered by the Hague LD in Caelus Lifesciences v. Pendulum Therapeutics (UPC-CFI-0001615/2026, 28 October 2026) concerning a PI application granted against Pendulum’s “Metabolic Daily” and “Glucose Control” products.
Caelus Lifesciences IP B.V. applied to the court for preliminary measures to stop Pendulum and another company (iHerb) from selling “Metabolic Daily” and “Glucose Control” in the UPC territory and Switzerland, alleging that they infringe their European patent EP 2753187 B2 for preventing and/or treating insulin resistance.
The court broke down claim 1 into the following features:
1.1 Eubacterium hallii and/or Alcaligenes faecalis
1.2 for use in preventing and/or treating
1.2.a insulin resistance
1.2.b and/or insulin resistance-related complications selected from metabolic syndrome, dyslipidemia, type 2 diabetes mellitus, and insulin resistance in endocrine diseases such as in obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes.
The patent described the bacteria Eubacterium hallii (E. hallii) as a butyrate-producing species of the genus Eubacterium. (Butyrate is a short-chain fatty acid which can influence insulin sensitivity and stimulate intestinal production of GLP-1, a hormone involved in regulating insulin secretion and blood glucose.)
Example 1 of the patent showed a positive correlation between E. hallii and the corrective effects of fecal matter transplantation. Example 3 presents mouse experiments where oral administration of the bacteria known as “L2-7”, characterised in the patent as being a strain of E. hallii, improved insulin resistance and fasting lipid profiles.
Several years after the patent’s 2011 priority date, a scientific publication by Shelly et al. proposed to reclassify E. hallii as the species Anaerobutyricum hallii, a member of a newly identified genus Anaerobutyricum (which is not in the same family as Eubacterium). Shelly et al. 2018 also characterised “L2-7” not as a strain of the newly identified A. hallii species, but rather as another species of the same genus; Anaerobutyricum soehngenii. The field has followed these reclassifications.
That left the LD with an intriguing question of claim construction. What does a claim referring to “E. hallii” mean?
The court construed the claim from the perspective of the skilled person at the priority date.
Pendulum and iHerb argued that claim 1 should be limited to “L2-7”, later named A. soehngenii, which had been used to demonstrate the therapeutic effects in the mouse experiments. The court disagreed, noting that as a “general rule, examples are not limiting and the claims recite E. hallii, without limitation.” The court also accepted Caelus’ assertion that Example 1 identified E. hallii (as the species) as being advantageous, thereby providing broader support.
At paragraph 5.4.6, the court held:
“Caelus also made sufficiently clear that E. hallii should therefore be interpreted as A. hallii in modern terminology, while the claim further encompasses strain L2-7, at the priority date assumed to belong to E. hallii (but later reclassified as not a strain but a species called A. soehngenii).”
Being proceedings for preliminary measures, not full merits proceedings, the LD Hague only assessed infringement and validity on a summary basis (which at the UPC is still fairly detailed). The court analysed, and dismissed, Pendulum and iHerb’s arguments of added matter, insufficient disclosure and obviousness. Of particular interest was that the patent benefits from a strong presumption of validity, having survived opposition and appeal proceedings at the EPO (being maintained in amended form).
Having found that the claims are not limited to “L2-7” (A. soehngenii), the court also dismissed Pendulum and iHerb’s arguments of non-infringement. It was not disputed that “Metabolic Daily” and “Glucose Control” both contain A. hallii, and the webpages selling these products show the following mechanistic diagram:

Among their non-infringement arguments was the assertion that claim 1 required the recited hallii bacteria, on its own, to produce the claimed therapeutic effect, and that “Metabolic Daily” and “Glucose Control”, in contrast, contained other components that contribute to their beneficial effects. Again, the court did not agree with the defendants, finding it “sufficiently plausible that hallii has a meaningful contribution to the effect” as emphasised by their marketing materials. This supported the court’s decision to award the preliminary injunction, alongside the findings that the patentee acted without undue delay in the circumstances.
Eliot is a highly valued partner at Mewburn Ellis and a key driver within the Life Sciences team. With a reputation for driving complex projects from inception to completion, he works with a diverse range of clients, from innovative startups to multinational corporations worldwide. Eliot handles a diverse client portfolio spanning the life sciences and MedTech sectors. A skilled patent prosecutor, Eliot also has wide experience of drafting patent applications on breakthrough technologies, as well as leading offensive and defensive opposition proceedings post-grant. Eliot is also experienced in handling Freedom to Operate projects and in performing due diligence, which have led to the successful completion of high value transactions and investment rounds.
Email: eliot.ward@mewburn.com
Stay up to date with our latest thinking.